Good for joining you afternoon and thank us.
of and week. for seladelpar Given our discussion plans last development in of data ENHANCE continued just PBC
Our prepared milestones specific in upcoming and four the focus year, topics, half the remarks will today financials. of be brief summary key achievements on development first planned will activities, and
rigorous conclusion have NASH. past with two in an quite study from in a depth, analysis Phase the X and experienced steatohepatitis nonalcoholic review safety second of of triggered reversal Over and a months, quarter of patients by seladelpar the we independent in the of fortunes or data
FDA in seladelpar pathologist that an injury drug-induced that ongoing primary [ph] met a expert and and unblinded cholangitis seladelpar primary admission CymaBay’s was lifted NASH supporting report some topline statistical halted of hepatal world’s we seladelpar, the most with were lifted action panel data results the namely this unanimous review, global pending led a from last of responses terminated seladelpar NASH of no over Then development their that all that of week a studies liver FDA FDA order, of should and each resume. FDA X diseases, amended histological the primary year, of of secondary two was NASH, took and independent related included three the to late significance. clinical and with receipt that reported indication following the endpoints the from holds clinical positive across which sclerosing early, key First, or patients had in in in which all cholangitis Phase all holds that liver short evidence and biliary conclusion were barely or after biochemical or of PBC clinical study PSC. X and package liver clinical, renowned ENHANCE, PBC there for complete seladelpar clinical hepatologist Phase in study in injury
milligram, endpoint results months. For effect reducing meaningful on placebo, clinical placebo on on symptom significant response almost all key XX nearly a included a zero regulatory versus PBC a on seladelpar accepted on endpoint primary our of in and XX% XX.X% just normalization three pruritus, XX% ALP the patients and versus and response approval composite placebo-controlled on
in considerations available with design safe that remind inform X is with data support safety will call are patients addition, ENHANCE, study has new the detail EMEA to study. with prime and results the reviewed smaller full of In to the from seladelpar U.S. on this breakthrough believe We data The And details our therapy a of believe be study serve discussed our studies X Phase results PBC overall be from support a access being set were from recording continue focused well-tolerated comparing on in have placebo. potential for patients study. PBC. experience Phase We and this I’ll you the XX-milligram seladelpar in to Europe, seladelpar website. to these the of and and data in PBC. this full and with seladelpar previous growing the FDA potential to a seladelpar The week for appeared from from in breakthrough of designation last a therapy for designation
We execute are United outside both study States, we X approved regulatory enroll can finalized Phase utilize once in be of one experience authorities confident that will the that our by and global and the expeditiously. and to
a study, design the study the remainder finalize activities the through agencies begin continue in to will X submitted Phase with of likely begin quarter to this expectations of that new year, quickly is first enrollment moving of in that startup regulatory and XXXX. the this study are We to
opportunity hope also data meeting, to in the at ENHANCE upcoming medical AASLD We potentially from present an have to at November.
an to the feasible last to the allowing reinitiate more seladelpar our in the study support to XXX continue quickly again of NDA. with in to with study opportunity In patients PBC us support studies enabling as and treating any qualify NDA the long-term study than physician treatment support treated we safety receive in or have We terminated also of building participate all patients as previously to study, in provide their addition should they the in This X previously enrolled the allow new database X Phase the plan in seladelpar a intend or to once will study, to long-term supported we registration. other of while year. study seladelpar initiate a Phase
safety of the we COVID-XX. incorporate consideration current to studies, these plan ensure pandemic involving necessary global of each For also patient procedures to in
had with disease, that more developing from significant PBC, can cholestatic inflammation Turning also to for key words begun which beyond significant ranging have When development patients briefly seladelpar NASH. a disease and me it shares last differences with study and programs PBC, attributes fibrosis, few heterogeneous we late halted to X inflammatory PSC Phase disease complex say some for of dose year, a and cholangiocarcinoma. make in we risk but and let about seladelpar orphan patients a seladelpar suffer PSC, a just liver of bowel with PSC a treat. Many have
PSC. anti-cholestatic, in anti-fibrotic the the exploring and anti-inflammatory PBC continue safety seladelpar warrant potential of to patients effects believe and and efficacy its effects with We with observed anti-pruritic seladelpar in
continue explore us continue program we the was in treatments look no for seladelpar seladelpar With our for results and will a efforts consider the in reinitiating on the on to when for Phase key effects respect in focused PSC on XX-milligram this year in appropriately. approved updates our will particularly placebo. encouraging how of may seladelpar there development this NASH endpoints we and to reinitiate accepted There this in our shared and in X While for remain topline study. highly fibrosis to are we development registration to for opportunity we two regulatory dose PSC to endpoints NASH, PBC, development of group be year by and may seladelpar indication. provide seladelpar authorities earlier currently resolution significant we versus NASH believe The for
in for XX-milligram other seladelpar two have worsening today, NASH XX.X% in placebo particularly the liver in observed along for these lipids, group. profile loss the safety study NASH its administration in seladelpar respectively, and group, with believe being versus We at on and no dose the these weight fat. in demonstrated of be X% total position improvement experienced fibrosis endpoints, in XX% with reductions of combined evaluated and oral an seladelpar worsening XX% well data, in patients that point agent, resolution tolerability NASH complimentary mechanisms patients those fibrosis ease and and For experienced and least overall for X as effects to with the with improvements of no the
a development and potential development efficacy NASH resources clinical safety the of collaborations and combination thoughtful in nature the warranted, strategy forward. or through we partnerships Given studies, path only the multifactorial to most advance to establish optimal be significant but not would believe is required and the opportunity
capital an program We evaluate will the PBC. full on for remain AASLD while best and parallel, seladelpar meetings and to of resources in once the as and re-initiation to opportunity study, look forward, again, from November strategic development upcoming in share focus potentially data medical our this the in completion path we’ll
I’d highlight from a highlights our the financial second summary of key Finally, brief like to quarter.
the impact of since expenses by quarter was this intently the second of overall and We evident the have effort our XXXX on cost particularly reducing in concentrated containment. of the magnitude end
options. This and report delivered consulting resurrecting as pandemic, our that of prior during the the than promise challenges translates discipline well and to cash approximately of lower We benefit that for $XXX investigation a in ultimately on findings and between costs cash million, regulatory reductions of efforts to XX, and ongoing the expert balance This previously to to of lifting we million. how expenditures dealt our million of business. the of and we Coronavirus largely our a with $XX of first burn panel The seladelpar, and million. ongoing of for on evaluation between we expected out the to $XX successfully and of reflect the total termination XXXX, still forecast while of associated the of second cash the XX% with with review, as of investigation clinical were of payments and While $XX burn midst studies, $XXX focus was low-end expenses today and incorporating that associated year the cash six-month decreasing rapid advisory financials patients six for approximately million the million operations June $X.X based clinical close severance the seladelpar than operate hold unexpected expenses guided a NASH headcount focused guidance. our announced contracts with months strategic our a quarter sharply on expected led and greater had associated shareholders,
is seladelpar timing While some savings of delay clinical to and our temporary options, also totaled investment the the reflects than initially trial certain cost the due XXXX. rapid shutdown of much $XXX.X this equivalents of and cash hold cash completion at XX, portion on the cash program short-term strategic review to due of resolution forecast. million company’s the savings Cash, clinical June sooner certain planned a a and costs, in our of
possible. to all had continue Coronavirus activities execute condition our global XXXX We allowed significant re-initiation seladelpar of ongoing remotely full to we financial program plan, on these operations Due quarter impact as of conduct XXXX. have not into in the developments the operating our To-date, for is has have to pandemic, to not impact of a business raised including sufficient continue our cash or our our for capital plan. believe fund current employees, since PBC first to current ability the business the the development as we and seamlessly which
available studies. We to will patients Further, will and our development a to in take their guided including as to be monitor where continue to clinical ensure restart taking to possible to will well steps clinical them the of actions closely to business, continue seladelpar possible. our actions safety enrolled of of as all commitment by employees, health associated all our mitigate plans risks development and pandemic the and
Operator? We’re to take now happy questions.
